ClinicalTrials.Veeva

Menu

Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients (RETROLA)

A

ARCAGY/ GINECO GROUP

Status

Completed

Conditions

Relapsed Ovarian Cancers Patients

Treatments

Drug: Olaparib

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT04152941
GINECO-OV-237

Details and patient eligibility

About

This is a national, multi center, retrospective observational cohort study that will be carried out by reviewing the medical records of patients with relapsed epithelial ovarian, fallopian tube, or peritoneal cancer treated with olaparib following response to platinum-based chemotherapy.

Enrollment

130 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients must be female ≥18 years of age
  • Patients with histologically confirmed ovarian cancer, primary peritoneal cancer and / or fallopian-tube cancer that were treated with olaparib in a real life-setting, between May 2014 to March 2017, whatever the line of therapy
  • Patients can be either alive or deceased at the time of medical record abstraction
  • Patients should not have any objection that anonymized data will be collected and subjected to automated processing.

Exclusion criteria

  • Patient that were given olaparib within a clinical trial

Trial contacts and locations

28

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems